Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 50

1.

Primary resistance to integrase strand-transfer inhibitors in Europe.

Casadellà M, van Ham PM, Noguera-Julian M, van Kessel A, Pou C, Hofstra LM, Santos JR, Garcia F, Struck D, Alexiev I, Bakken Kran AM, Hoepelman AI, Kostrikis LG, Somogyi S, Liitsola K, Linka M, Nielsen C, Otelea D, Paraskevis D, Poljak M, Puchhammer-Stöckl E, Staneková D, Stanojevic M, Van Laethem K, Zidovec Lepej S, Clotet B, Boucher CA, Paredes R, Wensing AM; SPREAD programme.

J Antimicrob Chemother. 2015 Jul 17. pii: dkv202. [Epub ahead of print]

PMID:
26188038
2.

Variation analysis of six HCV viral load assays using low viremic HCV samples in the range of the clinical decision points for HCV protease inhibitors.

Wiesmann F, Naeth G, Sarrazin C, Berger A, Kaiser R, Ehret R, Knechten H, Braun P.

Med Microbiol Immunol. 2015 Aug;204(4):515-25. doi: 10.1007/s00430-014-0364-z. Epub 2014 Nov 15.

3.

Low level HIV viremia is more frequent under protease-inhibitor containing firstline therapy than under NNRTI-regimens.

Wiesmann F, Braun P, Knickmann M, Knechten H.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19828. doi: 10.7448/IAS.17.4.19828. eCollection 2014.

4.

Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe.

Frentz D, Van de Vijver DA, Abecasis AB, Albert J, Hamouda O, Jørgensen LB, Kücherer C, Struck D, Schmit JC, Vercauteren J, Åsjö B, Balotta C, Beshkov D, Camacho RJ, Clotet B, Coughlan S, Griskevicius A, Grossman Z, Horban A, Kolupajeva T, Korn K, Kostrikis LG, Liitsola K, Linka M, Nielsen C, Otelea D, Paraskevis D, Paredes R, Poljak M, Puchhammer-Stöckl E, Sönnerborg A, Stanekova D, Stanojevic M, Van Wijngaerden E, Wensing AM, Boucher CA; SPREAD Programme.

BMC Infect Dis. 2014 Jul 21;14:407. doi: 10.1186/1471-2334-14-407.

5.

Patterns of transmitted HIV drug resistance in Europe vary by risk group.

Frentz D, van de Vijver D, Abecasis A, Albert J, Hamouda O, Jørgensen L, Kücherer C, Struck D, Schmit JC, Vercauteren J, Asjö B, Balotta C, Bergin C, Beshkov D, Camacho R, Clotet B, Griskevicius A, Grossman Z, Horban A, Kolupajeva T, Korn K, Kostrikis L, Linka KL, Nielsen C, Otelea D, Paraskevis D, Paredes R, Poljak M, Puchhammer-Stöckl E, Sönnerborg A, Stanekova D, Stanojevic M, Vandamme AM, Boucher C, Wensing A; SPREAD Programme.

PLoS One. 2014 Apr 10;9(4):e94495. doi: 10.1371/journal.pone.0094495. eCollection 2014.

6.

Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patients.

Xicoy B, Ribera JM, Müller M, García O, Hoffmann C, Oriol A, Hentrich M, Grande C, Wasmuth JC, Esteve J, van Lunzen J, Del Potro E, Knechten H, Brunet S, Mayr C, Escoda L, Schommers P, Alonso N, Vall-Llovera F, Pérez M, Morgades M, González J, Fernández A, Thoden J, Gökbuget N, Hoelzer D, Fätkenheuer G, Wyen C; PETHEMA Group and German HIV Lymphoma Cohort.

Leuk Lymphoma. 2014 Oct;55(10):2341-8. doi: 10.3109/10428194.2013.878933. Epub 2014 Feb 25.

PMID:
24397614
7.

Ambulatory care for HIV-infected patients: differences in outcomes between hospital-based units and private practices: analysis of the RESINA cohort.

Oette M, Reuter S, Kaiser R, Jensen B, Lengauer T, Fätkenheuer G, Knechten H, Hower M, Sagir A, Pfister H, Häussinger D; RESINA study group.

Eur J Med Res. 2013 Nov 21;18:48. doi: 10.1186/2047-783X-18-48.

8.

Prevalence of pharyngeal and rectal Chlamydia trachomatis and Neisseria gonorrhoeae infections among men who have sex with men in Germany.

Dudareva-Vizule S, Haar K, Sailer A, Wisplinghoff H, Wisplinghoff F, Marcus U; PARIS study group.

Sex Transm Infect. 2014 Feb;90(1):46-51. doi: 10.1136/sextrans-2012-050929. Epub 2013 Aug 6.

PMID:
23920398
9.

Limited cross-border infections in patients newly diagnosed with HIV in Europe.

Frentz D, Wensing AM, Albert J, Paraskevis D, Abecasis AB, Hamouda O, Jørgensen LB, Kücherer C, Struck D, Schmit JC, Åsjö B, Balotta C, Beshkov D, Camacho RJ, Clotet B, Coughlan S, De Wit S, Griskevicius A, Grossman Z, Horban A, Kolupajeva T, Korn K, Kostrikis LG, Liitsola K, Linka M, Nielsen C, Otelea D, Paredes R, Poljak M, Puchhammer-Stöckl E, Sönnerborg A, Stanekova D, Stanojevic M, Vandamme AM, Boucher CA, Van de Vijver DA; SPREAD Programme.

Retrovirology. 2013 Apr 3;10:36. doi: 10.1186/1742-4690-10-36.

10.

Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients.

Theys K, Deforche K, Vercauteren J, Libin P, van de Vijver DA, Albert J, Asjö B, Balotta C, Bruckova M, Camacho RJ, Clotet B, Coughlan S, Grossman Z, Hamouda O, Horban A, Korn K, Kostrikis LG, Kücherer C, Nielsen C, Paraskevis D, Poljak M, Puchhammer-Stockl E, Riva C, Ruiz L, Liitsola K, Schmit JC, Schuurman R, Sönnerborg A, Stanekova D, Stanojevic M, Struck D, Van Laethem K, Wensing AM, Boucher CA, Vandamme AM; SPREAD-programme.

Retrovirology. 2012 Oct 3;9:81. doi: 10.1186/1742-4690-9-81.

11.

Comparison of HIV-1 viral load assay performance in immunological stable patients with low or undetectable viremia.

Naeth G, Ehret R, Wiesmann F, Braun P, Knechten H, Berger A.

Med Microbiol Immunol. 2013 Feb;202(1):67-75. doi: 10.1007/s00430-012-0249-y. Epub 2012 Jun 15.

PMID:
22699843
12.

Epidemiology of transmitted drug resistance in chronically HIV-infected patients in Germany: the RESINA study 2001-2009.

Oette M, Reuter S, Kaiser R, Lengauer T, Fätkenheuer G, Knechten H, Hower M, Pfister H, Häussinger D; RESINA Study group.

Intervirology. 2012;55(2):154-9. doi: 10.1159/000332015. Epub 2012 Jan 24.

PMID:
22286886
13.

Risk factors associated with older age in treatment-naive HIV-positive patients.

Reuter S, Oette M, Kaiser R, Lengauer T, Fätkenheuer G, Rockstroh JK, Knechten H, Häussinger D.

Intervirology. 2012;55(2):147-53. doi: 10.1159/000332014. Epub 2012 Jan 24.

PMID:
22286885
14.

Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS.

Liptrott NJ, Pushpakom S, Wyen C, Fätkenheuer G, Hoffmann C, Mauss S, Knechten H, Brockmeyer NH, Hopper-Borge E, Siccardi M, Back DJ, Khoo SH, Pirmohamed M, Owen A; German Competence Network for HIV/AIDS.

Pharmacogenet Genomics. 2012 Jan;22(1):10-9. doi: 10.1097/FPC.0b013e32834dd82e.

15.

Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens.

Wyen C, Hendra H, Siccardi M, Platten M, Jaeger H, Harrer T, Esser S, Bogner JR, Brockmeyer NH, Bieniek B, Rockstroh J, Hoffmann C, Stoehr A, Michalik C, Dlugay V, Jetter A, Knechten H, Klinker H, Skaletz-Rorowski A, Fätkenheuer G, Egan D, Back DJ, Owen A; German Competence Network for HIV/AIDS Coordinators.

J Antimicrob Chemother. 2011 Sep;66(9):2092-8. doi: 10.1093/jac/dkr272. Epub 2011 Jun 29.

16.

The rainbow cohort: 96 week follow-up of saquinavir-containing regimens in previously antiretroviral therapy (ART)-naive and pre-treated but protease inhibitor (PI)-naive HIV-infected patients.

Knechten H, Stephan C, Mosthaf FA, Jaeger H, Carganico A, Lutz T, Schewe K, Mayr C, Wolf E, Wellmann E, Tappe A.

Eur J Med Res. 2011 Mar 28;16(3):93-100.

17.

The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?

Wiesmann F, Vachta J, Ehret R, Walter H, Kaiser R, Stürmer M, Tappe A, Däumer M, Berg T, Naeth G, Braun P, Knechten H.

AIDS Res Ther. 2011 Feb 13;8:7. doi: 10.1186/1742-6405-8-7.

18.

Prevalence of key resistance mutations K65R, K103N, and M184V as minority HIV-1 variants in chronically HIV-1 infected, treatment-naïve patients.

Metzner KJ, Rauch P, Braun P, Knechten H, Ehret R, Korn K, Kaiser R, Sichtig N, Ranneberg B, van Lunzen J, Walter H.

J Clin Virol. 2011 Feb;50(2):156-61. doi: 10.1016/j.jcv.2010.10.001. Epub 2010 Nov 4.

PMID:
21056001
19.

Safety and efficacy after switch to a saquinavir-containing antiretroviral regimen in protease inhibitor pretreated HIV-positive patients.

Stephan C, Jaeger H, Carganico A, Knecht G, Lutz T, Mayr C, Mosthaf FA, Koeppe S, Mueller M, Wolf E, Tappe A, Wellmann E, Knechten H.

Eur J Med Res. 2010 Sep 24;15(9):369-76.

20.

Safety and Efficacy in HIV-1-Infected Patients Treated with Ritonavir-Boosted Saquinavir Mesylate.

Knechten H, Lutz T, Pulik P, Martin T, Tappe A, Jaeger H.

Arch Drug Inf. 2010 Mar;3(1):26-36.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk